Subarachnoid haemorrhage (SAH), the most fatal of all cerebrovascular disturbances, results in death for 40-50% of patients suffering from the condition in the first months after the haemorrhage. The ...

A large population-based study found that statin use was significantly associated with a reduced risk of SAH. Research suggested potential clinical benefit to statins in this setting, particularly in ...

A meta-analysis of results from the Oxford Vascular Study indicates that rates of mortality associated with subarachnoid hemorrhage have decreased over the past 30 years. The study does not, however, ...

Contrary to the previous data, a Finnish study clarifies that smoking and high blood pressure do not protect from death in patients suffering from subarachnoid haemorrhage, the most lethal stroke ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Buscot and colleagues aimed to examine the optimal onset ...

Subarachnoid haemorrhage (SAH) is a life-threatening condition that kills, in contrast to other cerebrovascular disturbances, primarily healthy people of working age. Whereas smoking and high blood ...

Once the differential diagnosis is made, treatment can be initiated. While many may believe it is the sole responsibility of the physician or APN to diagnose the hyponatremic patient, it is important ...

Subarachnoid hemorrhage (SAH) is one of the most dangerous cerebrovascular disorders, with as many as 40% of patients dying within one month of the event. A study recently published in the journal ...

A Finnish study demonstrates that as little as half an hour of light exercise per week effectively protects against subarachnoid hemorrhage, the most lethal disorder of the cerebral circulation. Among ...

Please provide your email address to receive an email when new articles are posted on . “We’re all vulnerable to a bleeding stroke or a ruptured aneurysm; however, if you’re a routine marijuana user, ...

ATLANTA--(BUSINESS WIRE)--NeurOp, Inc., a clinical-stage biotechnology company focused on neurological and psychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has ...